These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
537 related articles for article (PubMed ID: 10100713)
1. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Davis TA; Czerwinski DK; Levy R Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713 [TBL] [Abstract][Full Text] [Related]
2. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Marcus R; Hagenbeek A Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982 [TBL] [Abstract][Full Text] [Related]
4. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
5. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Jazirehi AR; Bonavida B Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036 [TBL] [Abstract][Full Text] [Related]
6. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature. Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184 [TBL] [Abstract][Full Text] [Related]
7. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy]. Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050 [TBL] [Abstract][Full Text] [Related]
8. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy. Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299 [TBL] [Abstract][Full Text] [Related]
9. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma. Terui Y; Mishima Y; Sugimura N; Kojima K; Sakurai T; Mishima Y; Kuniyoshi R; Taniyama A; Yokoyama M; Sakajiri S; Takeuchi K; Watanabe C; Takahashi S; Ito Y; Hatake K Clin Cancer Res; 2009 Apr; 15(7):2523-30. PubMed ID: 19276251 [TBL] [Abstract][Full Text] [Related]
10. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463 [TBL] [Abstract][Full Text] [Related]
11. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment? Clavio M; Quintino S; Venturino C; Ballerini F; Varaldo R; Gatto S; Galbusera V; Garrone A; Grasso R; Canepa L; Miglino M; Pierri I; Gobbi M J Exp Clin Cancer Res; 2001 Sep; 20(3):351-8. PubMed ID: 11718214 [TBL] [Abstract][Full Text] [Related]
12. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505 [TBL] [Abstract][Full Text] [Related]
13. Mutation or polymorphism of the CD20 gene is not associated with the response to R-CHOP in diffuse large B cell lymphoma patients. Sar A; Perizzolo M; Stewart D; Mansoor A; Difrancesco LM; Demetrick DJ Leuk Res; 2009 Jun; 33(6):792-7. PubMed ID: 19054557 [TBL] [Abstract][Full Text] [Related]
14. [Rituximab resistance in B-cell lymphoma and its elimination]. Hatake K; Terui Y Gan To Kagaku Ryoho; 2009 Apr; 36(4):548-51. PubMed ID: 19381025 [TBL] [Abstract][Full Text] [Related]
16. Concepts in radiotherapy and immunotherapy: anti-CD20 mechanisms of action and targets. Maloney DG Semin Oncol; 2005 Feb; 32(1 Suppl 1):S19-26. PubMed ID: 15786022 [TBL] [Abstract][Full Text] [Related]
17. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Czuczman MS; Olejniczak S; Gowda A; Kotowski A; Binder A; Kaur H; Knight J; Starostik P; Deans J; Hernandez-Ilizaliturri FJ Clin Cancer Res; 2008 Mar; 14(5):1561-70. PubMed ID: 18316581 [TBL] [Abstract][Full Text] [Related]
18. Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab). Nishida M; Usuda S; Okabe M; Miyakoda H; Komatsu M; Hanaoka H; Teshigawara K; Niwa O Int J Oncol; 2007 Jul; 31(1):29-40. PubMed ID: 17549402 [TBL] [Abstract][Full Text] [Related]
19. Correspondence re: T. Davis et al., therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5: 611-615, 1999. Grillo-López AJ; Kunkel L Clin Cancer Res; 2000 Jan; 6(1):317-8. PubMed ID: 10656464 [No Abstract] [Full Text] [Related]
20. CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience. Bilić E; Femenić R; Konja J; Simat M; Dubravcić K; Batinić D; Ries S; Rajić L Coll Antropol; 2010 Mar; 34(1):171-5. PubMed ID: 20432747 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]